New Antibody IP Ruling by USPTO Sparks Cautious Optimism Among Biotech Attorneys

A May decision from top U.S. Patent and Trademark Office officials is giving some attorneys renewed hope that they will be able to secure antibody patents. However, legal professionals remain cautious, as they believe the agency’s ruling may not be sufficient to sway courts that have typically been hostile toward these patents. The ruling marks a significant moment for those engaged in the biotechnology sector, yet judicial reception to such patents remains uncertain. For more detailed information, visit the original article.